Clinical Trial Update: Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update on subcutaneous TEV-48125 for preventive treatment of migraine, with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• TEV-48125

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Migraine | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-06-15